Coronary Stents: A Global Strategic Business Report
San Jose, CA (PRWEB) November 16, 2011
Follow us on LinkedIn - Coronary artery disease is one of the leading causes of death among men and women in recent times. While one in every 5 deaths in the United States occurs due this disease, over fourteen million Americans currently are estimated to have active symptoms of this precarious condition. In this scenario, coronary stents have emerged as an innovative treatment as they assist in keeping the coronary artery open in patients suffering from the condition of coronary restenosis. During the 2006-2007 period, the market for such stents (classified into Bare Metal Stents and Drug Eluting Stents (DES)), witnessed a period of decline as the DES segment was hard hit by clinical reports that raised concerns relating to late-stent thrombosis. However, with the availability of new clinical evidence in 2008 that proved the safety and efficacy of the stents, the DES segment made a come back and is now driving the coronary stents market to reach new heights. With intentions to make great strides in the market, leading coronary stent producers, of late, have been engaged in taking up new research initiatives. Such efforts have ranged from formulating new material types, developing drug-coating techniques, to advancing stent surface technologies. Efforts have also being channelized towards developing less invasive and bioabsorbable coronary stents, which offer an effective alternative to the available invasive stents. As a result, the market is likely to witness many high-profile innovations over the next few years.
Coronary stents, despite finding extensive usage in the treatment of cardiac malfunctions and displaying strong growth in the market for medical equipment, are likely to encounter impediments that may risk growth of the market in the long-term. From widespread skepticism on the grounds of implantation safety of metal and drug content of stents and post stenting complications, to the availability of alternate therapies such as laser angioplasty and lesser invasive bypass surgeries, the market is likely to face challenges from many corners. In a quest to obviate such deficiencies, the cardiac care market, of late, has been avidly developing advanced techniques and simpler drug therapies that fix restenosis without the requirement of stenting. Cost benefits offered by such therapies are their unique selling propositions against pricey coronary stents, thereby curtailing the usage of coronary stents in cardiac procedures.
The global coronary stents market is led by the developed markets of United States and Europe, as stated by the new market research report on Coronary Stents, owing to an overwhelming number of angioplasty procedures, high awareness levels and extraordinary penetration levels in the regions. With coronary artery disease being the leading cause of death in the US, it is no surprise that the region is fuelling the maximum demand in the present scenario. The Asia-Pacific market presently accounts for a minor share of the global market, but is expected to display potential for rapid growth and development, fuelled by fast growing markets of China and India, The coronary stents market in Asia-Pacific is projected to witness fast track growth at a sturdy CAGR of over 10% over the analysis period. By product segment, the market for drug eluting stents accounts for a significant chunk of the global coronary stents market, bearing the torch for strong growth prospects.
The global coronary stents market is largely dominated by a handful of deep pocketed, international players who are the primary trendsetters and have a major presence in several countries worldwide. The rest of the market is highly fragmented with several medium and small players competing for stronger positioning and bargaining power. Key participants profiled in the report include Angiotech Pharmaceuticals, Abbott Vascular, Biosensors International, Boston Scientific Corp., Cordis Corporation, Medtronic, Inc, OrbusNeich, and Terumo Europe N.V.
The research report titled “Coronary Stents: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides useful market insights as well as comprehensive review of key market trends, industry overview, product introductions, recent industry activity and profiles of market players worldwide. The report profiles the international competition arena and provides pertinent market share data and product share tables. Analytics are presented in dollar value as well as in units for major geographic markets such as United States, Japan, Europe, Asia-Pacific and Rest of World. Major product segments analyzed include Bare Metal Stents, and Drug Eluting Stents. The study also provides historic data for an insight into market evolution over the period 2003 through 2008.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Coronary_Stents_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/
###
We're here to help.
Call 1-866-640-6397
©Copyright 1997-, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
